The Competition and Markets Authority (CMA) has had a very busy week making history (see my earlier post on the disqualification of directors for competition law breaches). This time, it has issued its largest ever fine for a massive increase in prices for an anti-epilepsy drug.

While most companies are not likely to see fines of this size, this case is a very good example of the range of sanctions available to the CMA, which include fines and a requirement that the price should be dropped in future. For other types of competition law breaches they can also impose director disqualification, as we saw earlier this week, or a requirement to sell or hive off parts of a business. 

These type of more practical sanctions are very different in concept to the usual range of sanctions for regulatory non-compliance and show the importance of this issue and the increasing confidence of the CMA in its role as a regulator.